Figure 1. Disease treatment and progression. Each point represents measurement of peripheral blood (PB) blast percentage (black), hemoglobin level (red) or platelets measurement (blue). First point represents diagnosis at day 0, C1D1 Aza + Ven represents cycle one day 1 of the treatment with azacitidine (Aza) and venetoclax (Ven), C1D1 cytarabine indicates cycle one day 1 of cytarabine treatment, C1D3 cytarabine + cladribine indicates cycle one day 3 of cytarabine and cladribine treatment. Last point represents the last day at the hospital, soon after the patient expired at a different institution.
Figure 2. Patient blasts show variable responses to FLT3 inhibitor treatment, with the highest efficacy of gilteritinib. Cells were seeded with graded concentrations (0 - 3.33 µM) of midostaurin, quizartinib and gilteritinib for 72 h, and cell viability was determined by CCK-8 assay. The graph depicts the IC50 values for each drug (a). Cells were seeded with 0, 0.5, or 1 µM of FLT3 inhibitor or dimethyl sulfoxide (DMSO). Cells were counted three times 72 h post-treatment with trypan blue (b). Statistical analysis was performed using one-way ANOVA, with adjusted P < 0.05 considered significant.
Figure 3. Gilteritinib treatment results in the lowest percentage of live cells among tested FLT3 inhibitors. Flow cytometry analysis of cells stained with propidium iodide (PI) was performed to evaluate cell death. Cells were first gated for the lymphocyte population based on side scatter and forward scatter, followed by gating cells on PI-positive and PI-negative (live cells) populations in reference to unstained control. FLT3: FMS-like tyrosine kinase 3; DMSO: dimethyl sulfoxide; FSC-A: forward scatter area.